DGAP-News: INJEX Pharma AG: INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin)
(firmenpresse) - DGAP-News: INJEX Pharma AG / Key word(s): Miscellaneous
INJEX Pharma AG: INJEX share prospectus approved by the German Federal
Financial Supervisory Authority (BaFin)
27.02.2013 / 10:17
---------------------------------------------------------------------
Corporate News: INJEX share prospectus approved by the German Federal
Financial Supervisory Authority (BaFin)
Berlin, February 27, 2013 - INJEX Pharma AG is pleased to announce that the
German Federal Financial Supervisory Authority (BaFin) approved yesterday
the share prospectus of the company. The prospectus is from now on
available on the Company's website at www.injex.com.
INJEX Pharma aims to achieve a listing on the regulated market of the
Frankfurt Stock Exchange (segment General Standard) - an approved
prospectus by BaFin is a precondition. A stock exchange listing on the
regulated market is delivering increased visibility on the capital markets
for the company and is part of the implementation of the growth strategy.
The desired listing in General Standard will broaden the shareholder base
of the company even more and will make it easier to trade the shares for
international investors.
The admission of shares is expected on March 11, 2013 in the regulated
market of the Frankfurt Stock Exchange in the General Standard segment. The
listing is expected on March 18, 2013. A change of this timetable is still
possible. The securities code number of the shares is ISIN: DE000A0STYL7,
the WKN number is WKN: A0STYL.
For further information on INJEX Pharma AG and its subsidiaries, please
refer to www.injex.com.
For further questions please contact our Investor Relations team directly:
INJEX Pharma AG
Investor Relations Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir(at)injex.com
INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.
End of Corporate News
---------------------------------------------------------------------
27.02.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
202460 27.02.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Pazoo Launches Newly Redesigned Website, Increases Online Presence
Datum: 27.02.2013 - 10:17 Uhr
Sprache: Deutsch
News-ID 233735
Anzahl Zeichen: 6440
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: INJEX Pharma AG: INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin)"
steht unter der journalistisch-redaktionellen Verantwortung von
INJEX Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
